Breast Biopsy Market By Product (Vacuum Assisted Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy), By Image Guided Technology (Mri Guided Breast Biopsy, Ultrasound Guided Breast Biopsy, Mammography Guided Stereotactic Biopsy, Ct Guided Biopsy, O

Breast Biopsy Market By Product (Vacuum Assisted Biopsy, Core Needle Biopsy, Fine Needle Aspiration Biopsy), By Image Guided Technology (Mri Guided Breast Biopsy, Ultrasound Guided Breast Biopsy, Mammography Guided Stereotactic Biopsy, Ct Guided Biopsy, Other Image Guided Breast Biopsy), By End User (Hospitals And Clinics, Diagnostic Centers): Global Opportunity Analysis and Industry Forecast, 2020-2030

The global breast biopsy market was estimated to be $658 million in 2020 and is estimated to reach $1082 million in 2030 with an expected CAGR of 5.1% from 2021 to 2030.Breast biopsy is a significant medical technology that is used in detection of irregular growth of cells and tissues for determination of underlying cancerous behavior possession. The Breast Biopsy market may be segmented using a variety of approaches.Breast biopsies are commonly done with Fine Needle Aspiration Biopsy, which is one of the least invasive procedures available and leaves no scarring. A needle is introduced through the dermal tissue of the breast to remove tissue. The other method involves using ultrasound radiation to guide the biopsy, which is also known as stereotactic needle biopsy in conjunction with a mammogram. During this treatment, the ultrasound monitor guides the needle to the target spot in the breast. Stereotactic mammography uses images acquired from various angles to pinpoint the site of the breast tumor, as well as where the needle will be put to get a breast biopsy sample.

Breast biopsy is a diagnostic process used to see if a small sample of breast tissue removed is malignant or not. A breast biopsy helps in locating the diseased tissue in breast and helps in further diagnosis. Factors that contribute to the rise in breast biopsy market are surge in consumption of alcoholic drinks, lack of exercise, and improper dietary habits. With surge in hormonal imbalance as a result of unhealthy lifestyle is also considered as a prominent factor that contributes in the rise of the market. However, limited awareness among female population and substandard healthcare facilities are factors that restrain the growth of breast biopsy market.

The pandemic of COVID-19 is predicted to have a detrimental impact on breast biopsy market growth. The pandemic had a number of negative consequences for breast biopsy market growth due to shutdown in services related to cancer screening. Owing to lockdowns in several nations to prevent the spread of COVID-19, hospitals, clinics, and diagnostic facilities were unable to deliver biopsy services. The surgeries got delayed due to risk of infections and use of protective equipment and hospital resources was limited to the COVID patients, thus creating a negative impact on breast biopsy market.

The breast biopsy market is segmented on the basis of product, image guided technology, end user, and region. On the basis of product, it is categorized into vacuum-assisted biopsy (VAB), core needle biopsy (CNB), and fine needle aspiration biopsy (FNAB). By image guided technology, it is classified into MRI-guided biopsy, ultrasound guided biopsy, mammography guided stereotactic biopsy, CT-guided biopsy, and others. On the basis of end user, it is bifurcated into clinics diagnostic centers and hospitals. By region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Germany, Russia, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, Singapore, Philippines, and rest of Asia-Pacific), and LAMEA (Brazil, Turkey, Israel, Saudi Arabia, South Africa, and rest of LAMEA).

The list of key players included in the report include Becton, Dickinson & company, Hologic, Inc., Cell-Signalling Technology, Danaher, QIAGEN, Illumina, Fujifilm, Medtronic, Bio-rad and Thermo Fisher Scientific Corp.

The other players in the value chain include Zenalux Biomedical, Inc., F. Hoffmann-La Roche Ltd., OncoCyte Corporation, Laboratory Corporation of America Holdings (Labcorp), Scion Medical Technologies, Planmed Oy, Aurora Imaging Technology Inc., Carestream Health, Cardinal Health, and PerkinElmer.

KEY BENEFITS FOR STAKEHOLDERS

The study gives a top to bottom investigation of the breast biopsy market, with most recent things and future appraisals to explain the imminent investment pockets.
It gives a quantitative investigation from 2020 to 2030 to engage the accomplices to gain by prevailing market opportunities.
Wide investigation by product type and end user determines the various trends and prevailing opportunities in the different market.
Complete examination of all land regions is given, which assist with determining the main opportunities.
Key market players are profiled and their strategies are investigated totally to expect the relentless standpoint of the market.

Key Market Segments


By Product

Vacuum Assisted Biopsy
Core Needle Biopsy
Fine Needle Aspiration Biopsy

By Image Guided Technology

Mri Guided Breast Biopsy
Ultrasound Guided Breast Biopsy
Mammography Guided Stereotactic Biopsy
Ct Guided Biopsy
Other Image Guided Breast Biopsy

By End User

Hospitals And Clinics
Diagnostic Centers

By Region

Europe
Germany
U.K.
Italy
France
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
North America
U.S.
Canada
Mexico
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA

Key Market Players

Ethicon Endo Surgery
Intact Medical Corporation
Galini SRL
Hologic Inc.
Leica Biosystems Nussloch GmbH
C. R. Bard, Inc.
Becton and Dickinson Company
Argon Medical Devices
Cook Medical Incorporated
Encapsule medical Devices LLC.